Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

HDL-C Response Variability to Niacin ER in US Adults.

Christian JB, Olson EJ, Allen JK, Lowe KA.

Cholesterol. 2013;2013:681475. doi: 10.1155/2013/681475. Epub 2013 Feb 26.

2.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

3.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
4.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
5.

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation.

Am J Cardiol. 2003 Mar 15;91(6):667-72.

PMID:
12633795
6.

Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels.

Scoffone HM, Krajewski M, Zorca S, Bereal-Williams C, Littel P, Seamon C, Mendelsohn L, Footman E, Abi-Jaoudeh N, Sachdev V, Machado RF, Cuttica M, Shamburek R, Cannon RO 3rd, Remaley A, Minniti CP, Kato GJ.

Am J Cardiol. 2013 Nov 1;112(9):1499-504. doi: 10.1016/j.amjcard.2013.06.035. Epub 2013 Sep 13.

7.

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern ME.

Atherosclerosis. 2007 Jun;192(2):432-7. Epub 2007 Jan 19.

PMID:
17239888
8.
9.

Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease.

Moore A, Phan BA, Challender C, Williamson J, Marcovina S, Zhao XQ.

J Clin Lipidol. 2007 Dec;1(6):620-5. doi: 10.1016/j.jacl.2007.09.001. Epub 2007 Sep 15.

PMID:
21291704
10.

Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.

Sharma M, Sharma DR, Singh V, Panwar RB, Hira HS, Mohan B, Kumar N, Sharma SK, Gupta R.

Vasc Health Risk Manag. 2006;2(1):87-93.

11.

A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.

Davidson MH, Donovan JM, Misir S, Jones MR.

Am J Cardiovasc Drugs. 2010;10(5):305-14. doi: 10.2165/11584310-000000000-00000.

PMID:
20860413
12.

Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.

Insull W Jr, McGovern ME, Schrott H, Thompson P, Crouse JR, Zieve F, Corbelli J.

Arch Intern Med. 2004 May 24;164(10):1121-7.

PMID:
15159270
13.

[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].

Li XP, Duan J, Zhao SP, Tan MY, Xu ZM, Zhang DQ.

Zhonghua Yi Xue Za Zhi. 2006 Sep 12;86(34):2399-403. Chinese.

PMID:
17156651
14.

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.

Linke A, Sonnabend M, Fasshauer M, Höllriegel R, Schuler G, Niebauer J, Stumvoll M, Blüher M.

Atherosclerosis. 2009 Jul;205(1):207-13. doi: 10.1016/j.atherosclerosis.2008.11.026. Epub 2008 Dec 3.

PMID:
19131065
15.
16.

A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.

Hunninghake DB, McGovern ME, Koren M, Brazg R, Murdock D, Weiss S, Pearson T.

Clin Cardiol. 2003 Mar;26(3):112-8.

17.

Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).

Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.

Am J Cardiol. 2008 Nov 15;102(10):1341-7. doi: 10.1016/j.amjcard.2008.07.010. Epub 2008 Sep 11.

PMID:
18993152
18.

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.

Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, Walter U, Peetz D, Lackner K, Blankenberg S, Munzel T.

Atherosclerosis. 2009 May;204(1):216-21. doi: 10.1016/j.atherosclerosis.2008.08.003. Epub 2008 Aug 12.

PMID:
18822413
19.

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.

Franceschini G, Favari E, Calabresi L, Simonelli S, Bondioli A, Adorni MP, Zimetti F, Gomaraschi M, Coutant K, Rossomanno S, Niesor EJ, Bernini F, Benghozi R.

J Clin Lipidol. 2013 Sep-Oct;7(5):414-22. doi: 10.1016/j.jacl.2013.06.007. Epub 2013 Jun 27.

PMID:
24079282
20.

Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.

King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE.

Am J Med. 1994 Oct;97(4):323-31.

PMID:
7942933

Supplemental Content

Support Center